Kentucky Attorney General Daniel Cameron announced today that the state will be allocating $42 million to research the therapeutic potential of the psychedelic substance ibogaine for the treatment of opioid addiction.
(Photo credit: Alamy Stock Photo)
Attorney General Cameron said at a press conference that the state will be using $42 million that was obtained via lawsuits against opioid manufacturers to study a potential key benefit of the psychedelic substance ibogaine. The funding will lead to the establishment of clinical trial sites: a state commission will coordinator with state colleges in order to facilitate the research.
Ibogaine is a “dissociative psychedelic with oneiric properties that has multiple aforementioned anti-addictive mechanisms, as well as the ability to generate therapeutic psychological insights”, according to the journal Progress in Brain Research.
“We need to explore a new approach. We have to invest in programs, in potential solutions, for tomorrow”, said AG Cameron. “I hope that the commission [tasked with overseeing the research effort] will seek and find the next big breakthrough and that its members will initiate the investigation and dialogue necessary to make Kentucky a leader in the 21st century opioid treatment”.
According to a statement made by the AG’s office ibogaine has shown anti-addictive effects and it “repairs, maintains, and protects brain tissue, boosts and regulates mood, and deep introspection resulting in profound psychotherapeutic improvements”.
More articles from The Marijuana Herald can be found below.
